아토시반 시장 규모 : 유형별, 용도별, 지역별, 범위 및 예측

Atosiban Market Size And Forecast

Atosiban Market size was valued at USD 422 Million in 2023 and is projected to reach USD 841 Million by 2030 , growing at a CAGR of 11.5% during the forecast period 2024-2030. The market for Atosiban is expanding due to rising rates of preterm delivery, numerous pregnancies, infections, and chronic illnesses like diabetes and high blood pressure among pregnant women. The Global Atosiban Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Atosiban Market Definition

A competitive vasopressin and oxytocin receptor antagonist, Atosiban is a synthetic nonpeptide desamino-oxytocin analog. Because of its capacity to lessen contractions and increase uterine receptivity by reducing intracytoplasmic calcium release and downregulating prostaglandin synthesis, it is used after assisted reproduction to prevent preterm birth and to stop premature labor.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Atosiban Market Overview

Atosiban is a potent activator of myometrial contractions and is crucial at the start of both term and preterm labor. Preterm birth rates are rising, fueling the market expansion for Atosiban. Prevalence is fueled by increased multiple pregnancies, infections, and chronic illnesses, including diabetes and high blood pressure among pregnant women.

The World Health Organization estimates that 15 million babies are born preterm each year, which is increasing. Between 5% and 18% of newborns are born preterm in 184 nations. A healthy pregnancy is heavily responsible for reducing preterm birth-related fatalities and problems. With the use of modern, cost-effective therapies, these tragedies must be avoided more frequently.

The trend toward personalized treatment is impacting the market for Atosiban. Genetic and pharmacogenomic investigations are aiding the identification of patient-specific characteristics that can enhance Atosiban treatment. Additionally, digital health tools like telemedicine and remote patient monitoring alter how Atosiban is administered and tracked, leading to better patient outcomes.

Some limitations and difficulties may prevent the market from expanding. Related regulatory issues, a lack of hospital infrastructure, and insufficient prenatal care education in rural areas constrain the market's expansion.

Global Atosiban Market Segmentation Analysis

The Global Atosiban Market is segmented on the basis of Type, Application, and Geography.

By Type

Injection

Concentrate

Based on the Type, The market is segmented into Injection and Concentrate. The Injection segment is anticipated to dominate the Global Atosiban market. The quick beginning of the effect of Atosiban injection is well established. It is helpful for instances where urgent tocolysis (inhibition of uterine contractions) is required since it can swiftly stop uterine contractions and delay preterm labor.

By Application

Hospitals

Online

Retail

Based on the Application, The market is segmented into Hospitals, Online, and Retail. The Hospitals segment is anticipated to dominate the Global Atosiban market. Most of the time, hospitals employ Atosiban, especially in labor and delivery or maternity wards. It is given intravenously by medical personnel to expectant mothers going through preterm labor.

By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on the Regional Analysis, Global Atosiban is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will hold the largest Global Atosiban market as preterm birth is still a significant healthcare concern. In recent years, preterm birth rates have increased in the area. This pattern has increased demand for medications such as Atosiban, which postpone preterm labor and lessen the risks of premature birth.

Key Players

The "Global Atosiban Market" study report will provide valuable insight emphasizing the global market. The major players in the market are

Pfizer, Emcure Pharmaceuticals, Teva API, Ferring Pharmaceuticals, Sun Pharma, Shanghai Soho-Yiming Pharmaceuticals, EVER Pharma, Hangzhou Longshine Bio-Tech, Cayman Chemical, Neore Pharmaceutical, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Bachem Group, Transo-Pharm Handels-GmbH, Rochem International Inc, Piramal Pharma Solutions.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features and innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories

Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Atosiban Market. We cover the major impacting factors driving the industry growth in the given region.

Porter's Five Forces

The image provided would further help to get information about Porter's five forces framework, providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Atosiban Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ATOSIBAN MARKET

• 1.1 Market Definition
• 1.2 Market Segmentation
• 1.3 Research Timelines
• 1.4 Assumptions
• 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data Mining
• 2.2 Data Triangulation
• 2.3 Bottom-Up Approach
• 2.4 Top-Down Approach
• 2.5 Research Flow
• 2.6 Key Insights from Industry Experts
• 2.7 Data Sources

3 EXECUTIVE SUMMARY

• 3.1 Market Overview
• 3.2 Ecology Mapping
• 3.3 Absolute Market Opportunity
• 3.4 Market Attractiveness
• 3.5 Global Atosiban Market Geographical Analysis (CAGR %)
• 3.6 Global Atosiban Market, By Type (USD Million)
• 3.7 Global Atosiban Market, By Application (USD Million)
• 3.8 Future Market Opportunities
• 3.9 Global Market Split
• 3.10 Product Life Line

4 GLOBAL ATOSIBAN MARKET OUTLOOK

• 4.1 Global Atosiban Evolution
• 4.2 Drivers
  • 4.2.1 Driver 1
  • 4.2.2 Driver 2
• 4.3 Restraints
  • 4.3.1 Restraint 1
  • 4.3.2 Restraint 2
• 4.4 Opportunities
  • 4.4.1 Opportunity 1
  • 4.4.2 Opportunity 2
• 4.5 Porters Five Force Model
• 4.6 Value Chain Analysis
• 4.7 Pricing Analysis
• 4.8 Macroeconomic Analysis

5 GLOBAL ATOSIBAN MARKET, BY TYPE

• 5.1 Overview
• 5.2 Injection
• 5.3 Concentrate

6 GLOBAL ATOSIBAN MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Online Pharmacies
• 6.4 Retail Pharmacies

7 GLOBAL ATOSIBAN MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Argentina
  • 7.5.3 Rest of Latin America
• 7.6 Middle-East and Africa
  • 7.6.1 UAE
  • 7.6.2 Saudi Arabia
  • 7.6.3 South Africa
  • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL Atosiban MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Developments
• 8.4 Company Regional Footprint
• 8.5 Company Industry Footprint
• 8.6 ACE Matrix

9 COMPANY PROFILES

• 9.1 Pfizer
  • 9.1.1 Company Overview
  • 9.1.2 Company Insights
  • 9.1.3 Product Benchmarking
  • 9.1.4 Key Development
  • 9.1.5 Winning Imperatives
  • 9.1.6 Current Focus & Strategies
  • 9.1.7 Threat from Competition
  • 9.1.8 SWOT Analysis
• 9.2 Emcure Pharmaceuticals
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Teva API
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Ferring Pharmaceuticals
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Sun Pharma
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Shanghai Soho-Yiming Pharmaceuticals
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 EVER Pharma
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Hangzhou Longshine Bio-Tech
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Cayman Chemical
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Neore Pharmaceutical
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments
• 9.11 Hikma Pharmaceuticals
  • 9.11.1 Overview
  • 9.11.2 Financial Performance
  • 9.11.3 Product Outlook
  • 9.11.4 Key Developments
• 9.12 Lupin Pharmaceuticals
  • 9.12.1 Overview
  • 9.12.2 Financial Performance
  • 9.12.3 Product Outlook
  • 9.12.4 Key Developments
• 9.13 Bachem Group
  • 9.13.1 Overview
  • 9.13.2 Financial Performance
  • 9.13.3 Product Outlook
  • 9.13.4 Key Developments
• 9.14 Transo-Pharm Handels-GmbH
  • 9.14.1 Overview
  • 9.14.2 Financial Performance
  • 9.14.3 Product Outlook
  • 9.14.4 Key Developments
• 9.15 Rochem International Inc
  • 9.15.1 Overview
  • 9.15.2 Financial Performance
  • 9.15.3 Product Outlook
  • 9.15.4 Key Developments
• 9.16 Piramal Pharma Solutions
  • 9.16.1 Overview
  • 9.16.2 Financial Performance
  • 9.16.3 Product Outlook
  • 9.16.4 Key Developments

10. VERIFIED MARKET INTELLIGENCE

• 10.1 About Verified Market Intelligence
• 10.2 Dynamic Data Visualization

11 Appendix

• 11.1 Related Research